CAJ | 학술논문

目的评价以紫杉醇为基础的化疗方案在可手术的三阴性乳腺癌患者新辅助治疗中的疗效与安全性.方法肿瘤大于2 cm,经穿刺病理确诊的ER、PR、Her均阴性的乳腺癌患者,随机分为三组进行治疗:A组为紫杉醇175mg/m2 D1,表阿霉素100mg/m2D1 q 21天;B组为紫杉醇175mg/m2D1,顺铂30 mg/m2 D1-D3 q 21天;C组为紫杉醇80 mg/m2 D1、D8、D15,顺铂30 mg/m2 D1-D3,q 28天.患者均在手术前接受4个周期新辅助治疗后进行根治性手术.比较三组的原发肿瘤病理完全缓解(tpCR)率和总体反应(OR)率,并观察患者不良反应.结果共入组31例患者,所有患者均按计划完成术前4个周期新辅助治疗.A组tpCR率为30.0%,OR率为90%;B组tpCR率为33.3%,OR率为100%;C组tpCR率为83.3%,OR率为91.7%;C组的tpCR率明显高于A、B两组(P＜0.05).三组患者均无需要调整剂量的严重不良反应.结论紫杉醇联合顺铂每周化疗方案在可手术的三阴性乳腺癌患者新辅助治疗中有较高的tpCR率,同时具有可靠的安全性.
목적 평개이자삼순위기출적화료방안재가수술적삼음성유선암환자신보조치료중적료효여안전성.방법 종류대우2 cm,경천자병리학진적ER、PR、Her균음성적유선암환자,수궤분위삼조진행치료:A조위자삼순175mg/m2 D1,표아매소100mg/m2D1 q 21천;B조위자삼순175mg/m2D1,순박30 mg/m2 D1-D3 q 21천;C조위자삼순80 mg/m2 D1、D8、D15,순박30 mg/m2 D1-D3,q 28천.환자균재수술전접수4개주기신보조치료후진행근치성수술.비교삼조적원발종류병리완전완해(tpCR)솔화총체반응(OR)솔,병관찰환자불량반응.결과 공입조31례환자,소유환자균안계화완성술전4개주기신보조치료.A조tpCR솔위30.0%,OR솔위90%;B조tpCR솔위33.3%,OR솔위100%;C조tpCR솔위83.3%,OR솔위91.7%;C조적tpCR솔명현고우A、B량조(P＜0.05).삼조환자균무수요조정제량적엄중불량반응.결론 자삼순연합순박매주화료방안재가수술적삼음성유선암환자신보조치료중유교고적tpCR솔,동시구유가고적안전성.
Objective To assess the efficacy and safety of neoadjuvant paclitexal-based chemotherapy in Chinese triple negative breast cancer. Methods Operable breast cancer patients with tumor size over 2 cm, ER negative, PgR negative, and Her-2 negative were enrolled. The included patients were randomized into 3 groups to receive 4 cycles neoadjuvant chemotherapy. Group A were treated with paclitaxel(175 mg/m2, D1) plus epirubicin (75mg/m2, D1) chemotherapy every 3 weeks; group B were treated with paclitaxel (175 mg/m2, D1) plus cisplatin(30 mg/m2, D1-D3) chemotherapy every 3 weeks; and group C were treated weekly with paclitaxel(175mg/m2, D1, D8,D15) plus cisplatin(30mg/m2, D1-D3) chemotherapy erery 4 weeks. The primary end point was primary tumor pathologic complete remission (tpCR) rate, and the secondary end point was overall response (OR) rate. Safety assessment was performed according to CTCAE v3.0. Results Thirty-one eligible patients were enrolled and randomized into 3 groups. All patients completed 4 cycles preoperative chemotherapy. In group A, tpCR rate was 30.0%, and OR rate was 90.0%, respectively. In group B, tpCR rate was 33.3%, and OR rate was 100.0%, respectively. In group C, tpCR rate was 83.3%, and OR rate was 91.7%, respectively. The tpCR rate of group C was much the other two groups' (P ＜ 0.05). No patient needed to reduce drug doses according to the Adverse Event. Conclusion Using weekly paclitexal plus cisplatin neoadjuvant chemotherapy to treat operable triple negative breast cancer patients has higher pCR rate, good tolerability, and safety.